Get the Stockscreener App
0.5552
1.05%
-0.0059
Pre-market:
.61
0.0548
+9.87%
Cue Biopharma Inc stock is traded at $0.5552, with a volume of 183.55K.
It is down -1.05% in the last 24 hours and down -23.02% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.5611
Open:
$0.5611
24h Volume:
183.55K
Relative Volume:
0.69
Market Cap:
$43.72M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.6101
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
-11.28%
1M Performance:
-23.02%
6M Performance:
-10.45%
1Y Performance:
-46.10%
1-Day Range:
$0.555
$0.5898
1-Week Range:
$0.5537
$0.6528
52-Week Range:
$0.54
$1.75
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.5552 | 44.18M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Will Cue Biopharma Inc. stock continue upward momentum2025 Price Momentum & Fast Gain Stock Trading Tips - Newser
Is Cue Biopharma Inc. stock a safe investment in uncertain marketsDip Buying & Stepwise Trade Signal Implementation - Newser
How Cue Biopharma Inc. stock reacts to inflationary pressuresTrade Signal Summary & Real-Time Volume Triggers - Newser
Is Cue Biopharma Inc. (1UC) stock dividend growth reliableSwing Trade & Community Consensus Picks - Newser
Is Cue Biopharma Inc. (1UC) stock testing key supportStop Loss & Long-Term Safe Investment Ideas - Newser
What Wall Street predicts for Cue Biopharma Inc. stock price2025 Breakouts & Breakdowns & Safe Entry Zone Identification - Newser
Will Cue Biopharma Inc. (1UC) stock benefit from infrastructure billQuarterly Earnings Report & Long-Term Capital Growth Strategies - Newser
How Cue Biopharma Inc. (1UC) stock moves in volatile trading sessionsOil Prices & High Conviction Buy Zone Alerts - Newser
Can Cue Biopharma Inc. stock rebound after recent weakness2025 Volume Leaders & Technical Buy Zone Confirmation - BỘ NỘI VỤ
Is Cue Biopharma Inc (CUE) positioned for future growth? - Setenews
Will Cue Biopharma Inc. stock benefit from AI adoptionMarket Risk Summary & Community Supported Trade Ideas - moha.gov.vn
[Form 4] Cue Biopharma, Inc. Insider Trading Activity - Stock Titan
Cue Biopharma Releases Updated Corporate Presentation - TipRanks
[8-K] Cue Biopharma, Inc. Reports Material Event | CUE SEC FilingForm 8-K - Stock Titan
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates - MSN
Can Cue Biopharma Inc. stock resist market sell offsGlobal Markets & Smart Swing Trading Alerts - newser.com
Will Cue Biopharma Inc. stock recover faster than peers2025 Top Gainers & Risk Controlled Daily Trade Plans - newser.com
Is Cue Biopharma Inc. stock dividend yield sustainableWeekly Trade Report & Verified Chart Pattern Signals - newser.com
Cue Biopharma Announces CMO Departure - TipRanks
Cue Biopharma Announces Departure of Chief Medical Officer - TradingView
Cue Biopharma, Inc. Announces Termination of Matteo Levisetti as Chief Medical Officer, Effective November 28, 2025 - MarketScreener
Why Cue Biopharma Inc. (1UC) stock benefits from AI revolutionEarnings Beat & Reliable Trade Execution Plans - newser.com
Is Cue Biopharma Inc. stock trading at a premium valuationPortfolio Risk Report & Risk Adjusted Buy/Sell Alerts - newser.com
Will Cue Biopharma Inc. (1UC) stock deliver compounding returns2025 Market WrapUp & Risk Controlled Daily Plans - newser.com
Why Cue Biopharma Inc. (1UC) stock could be next leader2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
How Cue Biopharma Inc. stock performs in rate cut cycles2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com
Can Cue Biopharma Inc. (1UC) stock expand revenue streams2025 Market Overview & Smart Investment Allocation Insights - newser.com
What dividend safety score for Cue Biopharma Inc. stockJuly 2025 Analyst Calls & Community Verified Watchlist Alerts - newser.com
Is Cue Biopharma Inc. stock gaining market shareWeekly Stock Analysis & Free Safe Capital Growth Stock Tips - newser.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Is Cue Biopharma Inc. stock attractive for hedge fundsBond Market & Fast Entry Momentum Trade Alerts - newser.com
Trend analysis for Cue Biopharma Inc. this week2025 Market WrapUp & Safe Capital Allocation Plans - newser.com
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):